{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:38:09Z","timestamp":1775540289364,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1163054"],"award-info":[{"award-number":["1163054"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1174523"],"award-info":[{"award-number":["1174523"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cct.2022.106761","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T11:28:04Z","timestamp":1650108484000},"page":"106761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial."],"prefix":"10.1016","volume":"117","author":[{"given":"Ellie","family":"Medcalf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiya","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy J.L.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2022.106761_bb0005","series-title":"Clinical Practice Guidelines for Diagnosis and Management of Melanoma","article-title":"What is the ideal setting, duration and frequency of follow-up for melanoma patients?","author":"Barbour","year":"2019"},{"key":"10.1016\/j.cct.2022.106761_bb0010","series-title":"The Cancer Council Australia and Australian Cancer Network SaNZGG: Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand","year":"2008"},{"issue":"Suppl. 5","key":"10.1016\/j.cct.2022.106761_bb0015","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0020","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamadermatol.2014.1952","article-title":"Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic","volume":"151","author":"Watts","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.cct.2022.106761_bb0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pon.3060","article-title":"Psychosocial aspects of post-treatment follow-up for stage I\/II melanoma: a systematic review of the literature","volume":"22","author":"Rychetnik","year":"2013","journal-title":"Psychooncology"},{"key":"10.1016\/j.cct.2022.106761_bb0030","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1200\/JCO.2010.34.2956","article-title":"Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma","volume":"29","author":"Turner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0035","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1245\/s10434-016-5263-7","article-title":"The MELFO-study: prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients-results after 1 year","volume":"23","author":"Damude","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0040","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1245\/s10434-019-07825-7","article-title":"The MELFO study: a multicenter, prospective, randomized clinical trial on the effects of a reduced stage-adjusted follow-up schedule on cutaneous melanoma IB-IIC patients-results after 3 years","volume":"27","author":"Deckers","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0045","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1245\/s10434-020-08758-2","article-title":"The MelFo study UK: effects of a reduced-frequency, stage-adjusted follow-up schedule for cutaneous melanoma 1B to 2C patients after 3-years","volume":"27","author":"Moncrieff","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0050","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamadermatol.2018.0021","article-title":"Patient preferences for follow-up after recent excision of a localized melanoma","volume":"154","author":"Lim","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.cct.2022.106761_bb0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jso.23278","article-title":"Follow-up of early stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals","volume":"107","author":"Rychetnik","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0060","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1245\/s10434-008-9985-z","article-title":"Methods of detection of first recurrence in patients with stage I\/II primary cutaneous melanoma after sentinel lymph node biopsy","volume":"15","author":"Moore Dalal","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0065","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1002\/cam4.3299","article-title":"Remote skin self-examination training of melanoma survivors and their skin check partners: a randomized trial and comparison with in-person training","volume":"9","author":"Robinson","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.cct.2022.106761_bb0070","series-title":"Cutaneous Melanoma","first-page":"851","article-title":"Surveillance and follow-up of melanoma patients","author":"Morton","year":"2020"},{"key":"10.1016\/j.cct.2022.106761_bb0075","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1158\/1055-9965.EPI-09-0310","article-title":"Efficacy of skin self-examination practices for early melanoma detection","volume":"18","author":"Pollitt","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.cct.2022.106761_bb0080","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.13550","article-title":"A pilot trial of mobile, patient-performed teledermoscopy","volume":"172","author":"Manahan","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cct.2022.106761_bb0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000493728","article-title":"Consumer acceptance and expectations of a mobile health application to photograph skin lesions for early detection of melanoma","volume":"235","author":"Koh","year":"2019","journal-title":"Dermatology"},{"key":"10.1016\/j.cct.2022.106761_bb0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jamadermatol.2021.4704","article-title":"Assessing the potential for patient-led surveillance after treatment of localized melanoma (MEL-SELF): a pilot randomized clinical trial","volume":"158","author":"Ackermann","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.cct.2022.106761_bb0100","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13063-021-05231-7","article-title":"Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial","volume":"22","author":"Ackermann","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.cct.2022.106761_bb0105","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/jama.2017.18556","article-title":"Guidelines for the content of statistical analysis plans in clinical trials","volume":"318","author":"Gamble","year":"2017","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.cct.2022.106761_bb0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12916-020-01706-7","article-title":"How to design a pre-specified statistical analysis approach to limit p-hacking in clinical trials: the pre-SPEC framework","volume":"18","author":"Kahan","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.cct.2022.106761_bb0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s12913-018-3291-7","article-title":"Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma","volume":"18","author":"Lim","year":"2018","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.cct.2022.106761_bb0120","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1245\/s10434-015-4589-x","article-title":"How often do patients with localized melanoma attend follow-up at a specialist center?","volume":"22","author":"Memari","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cct.2022.106761_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-017-0443-0","article-title":"What\u2019s the uptake? Pragmatic RCTs may be used to estimate uptake, and thereby population impact of interventions, but better reporting of trial recruitment processes is needed","volume":"17","author":"Bell","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cct.2022.106761_bb0130","series-title":"Clinical Prediction Models A Practical Approach to Development, Validation, and Updating","author":"Steyerberg","year":"2019"},{"key":"10.1016\/j.cct.2022.106761_bb0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1745-6215-15-139","article-title":"The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies","volume":"15","author":"Kahan","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.cct.2022.106761_bb0140","series-title":"Planning a Method for Covariate Adjustment in Individually-Randomised Trials: A Practical Guide","author":"Morris","year":"2021"},{"key":"10.1016\/j.cct.2022.106761_bb0145","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/bjd.18524","article-title":"A risk prediction model for the development of subsequent primary melanoma in a population-based cohort","volume":"182","author":"Cust","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cct.2022.106761_bb0150","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/sim.5991","article-title":"Variance reduction in randomised trials by inverse probability weighting using the propensity score","volume":"33","author":"Williamson","year":"2014","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2022.106761_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-016-0141-3","article-title":"A comparison of methods to adjust for continuous covariates in the analysis of randomised trials","volume":"16","author":"Kahan","year":"2016","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cct.2022.106761_bb0160","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2022.106761_bb0165","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2022.106761_bb0170","series-title":"Analysis of RCT Data with More than One Follow-Up Measurement, Analysis of Data from Randomized Controlled Trials","first-page":"15","author":"Twisk","year":"2021"},{"key":"10.1016\/j.cct.2022.106761_bb0175","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Analysing controlled trials with baseline and follow up measurements","volume":"323","author":"Vickers","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2022.106761_bb0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.conctc.2018.03.008","article-title":"Different ways to estimate treatment effects in randomised controlled trials","volume":"10","author":"Twisk","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.cct.2022.106761_bb0185","series-title":"Causal Inference: What if","author":"Hern\u00e1n","year":"2020"},{"key":"10.1016\/j.cct.2022.106761_bb0190","first-page":"125","article-title":"Comparability of randomised groups","volume":"34","author":"Altman","year":"1985","journal-title":"J. R. Stat. Soc. Ser. D (Stat.)"},{"key":"10.1016\/j.cct.2022.106761_bb0195","series-title":"Using Simulation Studies to Evaluate Statistical Methods","first-page":"2074","volume":"38","author":"Morris","year":"2019"},{"key":"10.1016\/j.cct.2022.106761_bb0200","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.2021.2825","article-title":"Interpreting the results of intention-to-treat, per-protocol, and as-treated analyses of clinical trials","volume":"326","author":"Smith","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2022.106761_bb0205","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/jech.2004.029496","article-title":"Estimating causal effects from epidemiological data","volume":"60","author":"Hern\u00e1n","year":"2006","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.cct.2022.106761_bb0210","series-title":"Marginal Structural Models and Causal Inference in Epidemiology","author":"Robins","year":"2000"},{"key":"10.1016\/j.cct.2022.106761_bb0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1740774511420743","article-title":"Beyond the intention-to-treat in comparative effectiveness research","volume":"9","author":"Hern\u00e1n","year":"2012","journal-title":"Clin. Trials (Lond. Engl.)"},{"key":"10.1016\/j.cct.2022.106761_bb0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jclinepi.2018.06.009","article-title":"Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials","volume":"103","author":"Murray","year":"2018","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.cct.2022.106761_bb0225","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cct.2022.106761_bb0230","series-title":"Dysplastic Nevus Syndrome: A Phenotypic Association of Sporadic Cutaneous Melanoma","first-page":"1787","volume":"46","author":"Elder","year":"1980"},{"key":"10.1016\/j.cct.2022.106761_bb0235","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jamadermatol.2014.514","article-title":"Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study","volume":"150","author":"Moloney","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.cct.2022.106761_bb0240","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamadermatol.2013.9313","article-title":"Clinical skin examination outcomes after a video-based behavioral intervention: analysis from a randomized clinical trial","volume":"150","author":"Janda","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.cct.2022.106761_bb0245","series-title":"Manual for the Depression Anxiety Stress Scales","author":"Lovibond","year":"1995"},{"key":"10.1016\/j.cct.2022.106761_bb0250","first-page":"1","article-title":"Development of a checklist tool to assess the quality of skin lesion images acquired by consumers using sequential mobile teledermoscopy","author":"Koh","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.cct.2022.106761_bb0255","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2589-7500(20)30001-7","article-title":"Accuracy of mobile digital teledermoscopy for skin self-examinations in adults at high risk of skin cancer: an open-label, randomised controlled trial","volume":"2","author":"Janda","year":"2020","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.cct.2022.106761_bb0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jamadermatol.2016.3949","article-title":"Technique standards for skin lesion imaging: a Delphi consensus statement","volume":"153","author":"Katragadda","year":"2016","journal-title":"JAMA Dermatol. (Chic. Ill.)"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422000878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422000878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:55:38Z","timestamp":1761555338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714422000878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S1551714422000878"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2022.106761","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial.","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2022.106761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106761"}}